Guo Nannan, Li Shanshan, Zhang Wen, Yu Changhai, Wang Hongwei, Zhang Yiming, Yu Jianqi
Department of Cardiothoracic Surgery, General Hospital of Chinese PLA, Beijing, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Aug;29(8):870-3.
To investigate the differential expressions of multidrug resistance protein 1 (MDR-1), ribonucleotide reductase M1(RRM-1), epidermal growth factor receptor(EGFR), excision repair cross-complementation group 1 (ERCC-1) in primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer (NSCLC), and analyze the relationship between the differential expressions and pathological types of NSCLC. Methods The expressions of MDR-1, RRM-1, EGFR and ERCC-1 were detected by immunohistochemistry in primary tumors and metastatic lymph nodes of 46 cases NSCLC patients. Wilcoxon signed ranks test was used to compare the differences in the expressions of these four molecular markers in primary lesions and metastatic lymph nodes. Fisher's exact test was used to analyze the relationship between differential expressions and pathological types of NSCLC.
The expressions of MDR-1, RRM-1, EGFR, ERCC-1 were observed in a variety of pathological types of NSCLC. The expression of ERCC-1 was significantly different between primary tumors and metastatic lymph nodes for lung adenocarcinoma (P=0.026). But the expressions of MDR-1, RRM-1, EGFR were not significantly different between primary tumors and metastatic lymph nodes for all pathological types of NSCLC (P>0.05). Conclusion The expression of MDR-1, RRM-1, EGFR, ERCC-1 of primary tumors and metastatic lymph nodes is found in all NSCLC. The expression of ERCC-1 is significantly different in primary tumors from in metastatic lymph nodes of lung adenocarcinoma.
探讨多药耐药蛋白1（MDR - 1）、核糖核苷酸还原酶M1（RRM - 1）、表皮生长因子受体（EGFR）、切除修复交叉互补组1（ERCC - 1）在非小细胞肺癌（NSCLC）患者原发性肿瘤和转移淋巴结中的差异表达，并分析这些差异表达与NSCLC病理类型之间的关系。方法 采用免疫组织化学法检测46例NSCLC患者原发性肿瘤和转移淋巴结中MDR - 1、RRM - 1、EGFR和ERCC - 1的表达。采用Wilcoxon符号秩和检验比较这四种分子标志物在原发性病变和转移淋巴结中的表达差异。采用Fisher确切概率法分析NSCLC差异表达与病理类型之间的关系。
在多种病理类型的NSCLC中均观察到MDR - 1、RRM - 1、EGFR、ERCC - 1的表达。肺腺癌原发性肿瘤和转移淋巴结中ERCC - 1的表达差异有统计学意义（P = 0.026）。但在所有病理类型的NSCLC中，原发性肿瘤和转移淋巴结中MDR - 1、RRM - 1、EGFR的表达差异无统计学意义（P>0.05）。结论 在所有NSCLC中均发现原发性肿瘤和转移淋巴结中有MDR - 1、RRM - 1、EGFR、ERCC - 1的表达。肺腺癌原发性肿瘤和转移淋巴结中ERCC - 1的表达差异有统计学意义。
